10 August 2017
Visiongain has launched a new pharma report World Bleeding Disorders Treatment Market 2017-2027: Forecast and Analysis by Indication (Haemophilia A, Haemophilia B, Von Willebrand Disease), Drug Class (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants) and Geography
Bleeding disorders are medical conditions wherein blood coagulation is dysfunctional due to which prolonged bleeding can occur when the person meets with an injury, trauma or during surgery. People with haemophilia lack, either partially or completely, an essential clotting factors needed to form stable blood clots. People with haemophilia do not bleed any faster than normal, but they can bleed for a longer duration.
Haemophilia A is a hereditary blood coagulation disorder. It is an X-linked, genetic bleeding disorder often caused by a defective or missing clotting protein known as factor VIII. Haemophilia B is sometimes also known as Christmas disease (named after Stephen Christmas, the first patient described with this disease) or Factor IX (FIX) deficiency. It is a genetic bleeding disorder caused by defective or missing factor IX. Von Willebrand disease (VWD) is a genetic bleeding disorder, which caused by defective or missing Von Willebrand factor (VWF), a clotting protein.
Apart from the bleeding disorders mentioned above, other forms of bleeding disorders also exist that are not very prominently known due to their low prevalence rate
The lead Visiongain report analyst for this report commented; “In recent years, the treatment of cancer has undergone a shift from replacement therapies to genetic/ gene therapies. Recombinant clotting factors are emerging as promising treatment options for haemophilia and bleeding disorder types. However, treatment of haemophilia through administration of factor concentrates remains to be the mainstream mode of prophylaxis. This form of replacement therapy is also called as prophylactic or preventive therapy. However, the dosage intervals for replacement factors to treat haemophilia and bleeding disorders continue to shrink as drugs such as Alprolix (Biorevativ) have been instrumental in reducing the dosage to once in every 10 days. This itself acts as a great opportunity as global market players and venture capitalists around the world are investing research, capital and time to develop efficient haemophilia and other bleeding disorder treatment therapeutics with the largest dosage intervals.”
The Bleeding Disorder Treatment market is highly competitive with many different players entering the market. The report discusses selected leading companies in the market. Notable companies in the POC diagnostics market include Novo Nordisk, Bristol-Myers Squibb, BMS, Pfizer, Bayer AG, CSL, Grifols S.A., Octapharma AG, Shire, Sanofi and Kendrion S.P.A.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The colon targeting drug delivery market has been used various polymers including biodegradable polymers, guar gum, pectin, chondroitin sulfate, dextran, chitosan, cyclodextrin, inulin, amylose, locust bean gum, and others
23 September 2019
Diagnostic imaging technology such as MRI and CT scans has become more precise and accessible, due to which radiology has increasingly become a key foundation of modern medicine.
20 September 2019
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.